BPC-157: The Gut-Brain Peptide That Repairs What Training Breaks
your gastric mucosa produces a 15 amino acid peptide. it is found in gastric juice. dr. dieter sikiric at the university of zagreb has been studying it since the 1990s. the research covers wound healing, tendon repair, gut lining restoration, neuroprotection, and blood pressure stabilization.
that peptide is bpc-157. body protection compound, 157 amino acids in the longer sequence. the 15-mer fragment is the research compound.
here is what the data shows, what it does not show, and the protocol people actually run.
The Mechanism
bpc-157 is an angiogenic peptide. its primary documented action is accelerating the formation of new blood vessels (angiogenesis) in injured tissue. blood vessel formation is the rate-limiting step in most soft tissue repair — tendons, ligaments, muscle, gut lining. you have to grow vascular supply before you can grow structural tissue.
the secondary mechanism is nitric oxide pathway modulation. bpc-157 upregulates NO synthesis in endothelial cells, which affects both blood pressure and local tissue perfusion. this is likely why the tendon data is so consistent — tendons are chronically underperfused because they have poor baseline vascularity.
the third mechanism is gut barrier restoration. bpc-157 reduces permeability in intestinal epithelial tissue and reverses NSAID-induced damage in animal models. this is the original research from sikiric — gastric ulcer healing. the gut-repair data is the most robust in the library.
one important mechanism absent from the data: anabolic. bpc-157 does not stimulate IGF-1, does not affect testosterone, does not increase protein synthesis directly. it is not a performance-enhancing peptide. it is a repair signal. the distinction matters because people who run it expecting strength gains will be disappointed. people who run it because a tendon is struggling will not be.
What The Research Shows
the tendon repair data is the strongest. achilles tendon transection studies in rats show significantly accelerated tendon-to-bone reattachment with systemic bpc-157. the sikiric lab has replicated this across multiple injury models.
the gut barrier data: bpc-157 reverses ethanol-induced gastric lesions and NSAID-associated gut damage in animal models. the mechanism is the NO pathway and prostaglandin upregulation, which explains the anti-ulcer effect.
neurological data: bpc-157 shows neuroprotective effects in CNS injury models and has been tested in dopaminergic pathways — some data suggesting it can attenuate the dopamine depletion from chronic stimulant use. this is not the primary use case but it is why it appears in some nootropic recovery stacks.
the honest limitation: all the mechanism data is animal studies. human clinical trials are limited. the sikiric lab has run some human case series but not controlled RCTs. you are working with strong animal data and a plausible human mechanism, not clinical trial proof.
Who Actually Needs It
three use cases where the mechanism matches the problem:
1. Soft tissue injury that is not resolving on its own. achilles tendinopathy, rotator cuff issues, patellar tendon problems, plantar fasciitis. anything that has been chronic for more than 6-8 weeks and is not responding to rest and PT. the vascularity mechanism is directly relevant. these tissues are poorly perfused and healing slowly for that reason.
2. Gut barrier dysfunction. leaky gut, NSAID-damaged gut lining, chronic inflammation from training, recovery from food poisoning or antibiotic course. the gastric data is the original and most replicated body of evidence.
3. Post-injury recovery after surgery or acute damage. the angiogenic mechanism is most useful when there is structural damage that needs vascular supply to rebuild. post-surgical recovery windows are where this gets the most consistent reports of faster return to function.
what it is not: a daily supplementation compound for healthy tissue. running it continuously with no injury to repair is wasting cost and potentially desensitizing the repair pathway.
The Protocol
dosing:
- low dose: 250mcg per injection
- standard dose: 500mcg per injection
- most protocols: 250-500mcg once or twice daily
route:
- subcutaneous injection (most common) — into fat tissue near the injury site if possible, or abdomen
- intranasal — less bioavailability but no injection required; 200mcg per nostril per dose
- oral — the original gastric research used oral administration; gut issues are the primary use case for oral
cycle:
- 4 to 8 weeks on, 4 weeks off minimum
- for injury resolution: run until the tissue feels healed, then stop
- do not run indefinitely; this is a repair signal, not a maintenance supplement
when to run it:
- active injury period, not maintenance
- if using for gut: run during the restoration period, not long-term
- if stacking: works alongside tb-500 (another repair peptide with different mechanism), not redundant
what to watch:
- injection site: subcutaneous, not IM; smaller needle (30g insulin needle)
- reconstitution: 1ml bacteriostatic water per 5mg vial
- storage: refrigerate reconstituted; dry peptide stable at room temperature
The Sourcing Question
peptide quality in the grey market is highly variable. the main failure modes are underdosing, wrong amino acid sequence, and contamination from poor manufacturing.
vendors worth using publish third-party HPLC certificates. the certificate should confirm peptide purity above 98% and show the correct molecular weight.
limitless life nootropics and pure rawz both publish COAs. yourprotocol carries pharmaceutical-grade peptides with higher QC standards and higher prices — appropriate if you are running post-surgical protocols where certainty matters more than cost.
avoid any vendor that does not publish current lab documentation.
The Stack Context
bpc-157 does not compete with cognitive performance compounds. it operates on a completely different axis — tissue repair, not neural performance.
if you are running an armodafinil + citicoline + bromantane stack for cognitive output, bpc-157 is not part of that stack. it is orthogonal.
where it appears alongside cognitive compounds: if chronic gut inflammation is the thing reducing cognitive clarity (gut-brain axis is real and the research is solid), restoring gut barrier function with bpc-157 can improve the baseline from which everything else operates. gut issues suppress cognitive function more than most people account for.
the full stack context lives at twentystack.substack.com/p/the-stack
What To Expect
week 1-2: possibly nothing subjective, or mild warmth at injection site week 3-4: if injury-driven, reduced pain and improved range of motion typically reported week 6-8: functional improvement in the target tissue
the effects are not acute and subjective the way modafinil is. this is background repair. you notice it when the thing that was limiting you stops limiting you.
people who get disappointed by bpc-157 are usually running it with no active injury to repair, or expecting performance enhancement instead of repair. if the problem it solves is the problem you have, the data supports using it.
tell me the injury or gut issue you are working with and i will tell you whether bpc-157 is the right tool or whether a different intervention has a stronger evidence base for your specific situation.